Skip to main content

Table 3 Dose–volume histogram results for OARs

From: Dosimetric feasibility of moderately hypofractionated/dose escalated radiation therapy for localised prostate cancer with intensity-modulated proton beam therapy using simultaneous integrated boost (SIB-IMPT) and impact of hydrogel prostate-rectum spacer

OARs Range Mean ± SD
Bladder
Volume 81.2–477.8 231.8 ± 131.8
Dmax 72.20–75.00 73.51 ± 0.70
Dmean 6.61–38.86 20.81 ± 9.57
Dmedian 0.16–39.69 10.85 ± 11.91
BV73Gy 0–4.0 0.74 ± 1.12
BV72Gy 0.03–11.37 4.14 ± 3.37
BV70Gy 0.61–17.78 7.85 ± 5.51
BV68.4 Gy 0.89–20.69 9.34 ± 6.36
BV65Gy 1.53–24.83 11.87 ± 7.38
BV60Gy 2.50–29.69 15.07 ± 8.78
BV55Gy 3.48–36.65 18.05 ± 10.13
BV50Gy 4.67–40.65 20.62 ± 11.03
BV40Gy 6.73–49.67 25.45 ± 12.83
BV30Gy 9.15–58.30 30.24 ± 14.43
BV20Gy 11.95–67.98 35.79 ± 16.31
BV10Gy 16.12–80.30 43.49 ± 18.61
Rectum
Volume 135.2–231.1 179.3 ± 27.0
Dmax 71.02–76.00 73.49 ± .99
Dmean 9.73–36.39 20.84 ± 6.14
Dmedian 1.60–38.41 9.50 ± 8.34
RV73Gy 0.00–1.53 0.31 ± 0.43
RV72Gy 0.00–6.66 1.94 ± 1.69
RV70Gy 0.05–10.72 4.64 ± 3.28
RV68.4 Gy 0.15–12.64 6.03 ± 3.89
RV66Gy 0.37–15.83 7.85 ± 4.70
RV65Gy 0.51–17.69 8.56 ± 5.0
RV62Gy 1.05—23.25 10.68 ± 5.92
RV60Gy 1.82–26.75 12.14 ± 6.29
RV55Gy 3.12–33.46 15.90 ± 7.03
RV50Gy 4.57–38.92 19.16 ± 7.71
RV40Gy 8.26–48.65 24.87 ± 8.97
RV30Gy 12.61–56.85 30.54 ± 9.96
RV20Gy 18.25–64.97 37.01 ± 10.83
RV10Gy 26.67–74.97 46.13 ± 11.63
Femoral head
Right Dmax 30.60–47.60 34.3 ± 4.28
Right Dmean 17.26–31.26 26.73 ± 3.5
Left Dmax 30.60–50.00 34.38 ± 4.16
Left Dmean 18.14–31.35 27.02 ± 3.59
Penile bulb
Dmean 2.96–61.43 23.18 ± 19.32
  1. *Dose in Gy; BVXGy = Percentage of bladder volume received X dose; RVXGy = Percentage of rectal volume received X dose